CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: furofuran
Accession: CHEBI:47790
browse the term
Definition: Organic heterobicyclic compounds containing a two furan rings ortho-fused to each other.
Synonyms: related_synonym: furofurans
G
Acaca
acetyl-CoA carboxylase alpha
multiple interactions decreases expression
ISO
[loliolide co-treated with pinoresinol] results in decreased expression of ACACA protein pinoresinol results in decreased expression of ACACA protein
CTD
PMID:31610126
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
G
Fasn
fatty acid synthase
multiple interactions decreases expression
ISO
[loliolide co-treated with pinoresinol] results in decreased expression of FASN protein pinoresinol results in decreased expression of FASN protein
CTD
PMID:31610126
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
G
Nr1h2
nuclear receptor subfamily 1, group H, member 2
multiple interactions
ISO
pinoresinol results in increased ubiquitination of and results in increased degradation of and results in decreased expression of NR1H2 protein
CTD
PMID:31610126
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
G
Nr1h3
nuclear receptor subfamily 1, group H, member 3
multiple interactions
ISO
pinoresinol results in increased ubiquitination of and results in increased degradation of and results in decreased expression of NR1H3 protein
CTD
PMID:31610126
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions
ISO
pinoresinol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
CTD
PMID:21191767
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Srebf1
sterol regulatory element binding transcription factor 1
decreases expression multiple interactions
ISO
pinoresinol results in decreased expression of SREBF1 protein [loliolide co-treated with pinoresinol] results in decreased expression of SREBF1 protein
CTD
PMID:31610126
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
G
Tnf
tumor necrosis factor
decreases secretion
ISO
pinoresinol results in decreased secretion of TNF protein
CTD
PMID:29740324
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
G
Abcb1a
ATP binding cassette subfamily B member 1A
multiple interactions
ISO
[sesamin affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin
CTD
PMID:18204840
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
G
Aifm1
apoptosis inducing factor, mitochondria associated 1
multiple interactions
EXP
sesamin affects the reaction [Glucose affects the localization of AIFM1 protein]
CTD
PMID:22524206
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO EXP
sesamin inhibits the reaction [nickel sulfate results in increased expression of BAX protein] sesamin affects the reaction [Glucose affects the expression of BAX protein]
CTD
PMID:22524206 PMID:23317420
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
G
Bcl2
BCL2, apoptosis regulator
multiple interactions
ISO EXP
sesamin inhibits the reaction [nickel sulfate results in decreased expression of BCL2 protein] sesamin affects the reaction [Glucose affects the expression of BCL2 protein]
CTD
PMID:22524206 PMID:23317420
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Casp3
caspase 3
multiple interactions
ISO EXP
sesamin inhibits the reaction [nickel sulfate results in increased cleavage of CASP3 protein] sesamin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]
CTD
PMID:22524206 PMID:23317420
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
G
Cat
catalase
decreases activity multiple interactions
EXP ISO
sesamin results in decreased activity of CAT protein sesamin inhibits the reaction [nickel sulfate results in decreased activity of CAT protein] sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CAT protein]; sesamin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]
CTD
PMID:19794909 PMID:23317420 PMID:26825964
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Cdh1
cadherin 1
increases expression
ISO
sesamin results in increased expression of CDH1 mRNA; sesamin results in increased expression of CDH1 protein
CTD
PMID:33561518
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
G
Ctnnb1
catenin beta 1
increases expression
ISO
sesamin results in increased expression of CTNNB1 mRNA; sesamin results in increased expression of CTNNB1 protein
CTD
PMID:33561518
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
G
Fads1
fatty acid desaturase 1
decreases activity
EXP
sesamin results in decreased activity of FADS1 protein
CTD
PMID:14974737
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
G
Gsr
glutathione-disulfide reductase
increases activity
EXP
sesamin results in increased activity of GSR protein
CTD
PMID:19835851
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
G
Il1b
interleukin 1 beta
multiple interactions
ISO
sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B mRNA]; sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B protein]
CTD
PMID:22919443
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
G
Il6
interleukin 6
multiple interactions
ISO EXP
sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 mRNA]; sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]
CTD
PMID:19794909 PMID:22919443
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
G
Nos2
nitric oxide synthase 2
decreases expression multiple interactions
EXP
sesamin results in decreased expression of NOS2 protein sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOS2 protein]
CTD
PMID:19794909 PMID:22919443
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
G
Parp1
poly (ADP-ribose) polymerase 1
multiple interactions
EXP
sesamin inhibits the reaction [Glucose results in increased cleavage of PARP1 protein]
CTD
PMID:22524206
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
G
Sod2
superoxide dismutase 2
multiple interactions
EXP
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [sesamin inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [sesamin results in increased expression of and results in increased activity of SOD2 protein]; sesamin inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]; sesamin results in increased expression of and results in increased activity of SOD2 protein
CTD
PMID:24211423
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Th
tyrosine hydroxylase
multiple interactions
EXP
sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TH protein]
CTD
PMID:19794909
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
G
Tnf
tumor necrosis factor
multiple interactions
ISO
sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF mRNA]; sesamin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]
CTD
PMID:22919443
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions
ISO
syringaresinol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
CTD
PMID:21191767
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Ache
acetylcholinesterase
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in increased expression of ACHE protein]
CTD
PMID:31077737
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
G
Bdnf
brain-derived neurotrophic factor
multiple interactions
ISO
[acanthoside B co-treated with Scopolamine] results in increased expression of BDNF protein
CTD
PMID:31077737
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
G
Cat
catalase
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in decreased activity of CAT protein]
CTD
PMID:31077737
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Creb1
cAMP responsive element binding protein 1
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in decreased phosphorylation of CREB1 protein]
CTD
PMID:31077737
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
G
Il10
interleukin 10
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in decreased expression of IL10 protein]
CTD
PMID:31077737
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
G
Il1b
interleukin 1 beta
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL1B protein]
CTD
PMID:31077737
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
G
Il6
interleukin 6
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in increased expression of IL6 protein]
CTD
PMID:31077737
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
G
Nos2
nitric oxide synthase 2
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in increased expression of NOS2 protein]
CTD
PMID:31077737
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
G
Ntrk2
neurotrophic receptor tyrosine kinase 2
multiple interactions
ISO
[acanthoside B co-treated with Scopolamine] results in increased phosphorylation of NTRK2 protein
CTD
PMID:31077737
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
G
Ptgs2
prostaglandin-endoperoxide synthase 2
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in increased expression of PTGS2 protein]
CTD
PMID:31077737
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
G
Tnf
tumor necrosis factor
multiple interactions
ISO
acanthoside B inhibits the reaction [Scopolamine results in increased expression of TNF protein]
CTD
PMID:31077737
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
G
Angpt2
angiopoietin 2
decreases expression
ISO
norcantharidin results in decreased expression of ANGPT2 mRNA; norcantharidin results in decreased expression of ANGPT2 protein
CTD
PMID:16681930
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
G
Atf4
activating transcription factor 4
multiple interactions increases expression
ISO
[norcantharidin co-treated with Paclitaxel] results in increased expression of ATF4 protein; Paclitaxel promotes the reaction [norcantharidin results in increased expression of ATF4 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of ATF4 protein]
CTD
PMID:34272796
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
G
Aurka
aurora kinase A
multiple interactions
ISO
[Paclitaxel results in decreased susceptibility to norcantharidin] which results in increased expression of AURKA protein
CTD
PMID:34272796
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
G
Bad
BCL2-associated agonist of cell death
increases expression
ISO
norcantharidin results in increased expression of BAD protein
CTD
PMID:21266192
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
G
Bak1
BCL2-antagonist/killer 1
increases expression
ISO
norcantharidin results in increased expression of BAK1 protein alternative form
CTD
PMID:29193574
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
G
Bax
BCL2 associated X, apoptosis regulator
increases expression
ISO
norcantharidin results in increased expression of BAX protein
CTD
PMID:21266192
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
G
Bcl2
BCL2, apoptosis regulator
increases phosphorylation decreases expression
ISO
norcantharidin results in increased phosphorylation of BCL2 protein norcantharidin results in decreased expression of BCL2 protein
CTD
PMID:21266192 PMID:29193574
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bcl2l1
Bcl2-like 1
decreases expression
ISO
norcantharidin results in decreased expression of BCL2L1 protein
CTD
PMID:21266192 PMID:29193574
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
G
Bcl2l11
Bcl2-like 11
increases expression
ISO
norcantharidin results in increased expression of BCL2L11 protein alternative form
CTD
PMID:29193574
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
G
Bid
BH3 interacting domain death agonist
increases expression
ISO
norcantharidin results in increased expression of BID protein modified form
CTD
PMID:29193574
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
G
Casp3
caspase 3
increases activity multiple interactions increases expression
ISO
norcantharidin results in increased activity of CASP3 protein Paclitaxel promotes the reaction [norcantharidin results in increased expression of CASP3 protein modified form]; U 0126 inhibits the reaction [norcantharidin results in increased expression of CASP3 protein modified form]
CTD
PMID:20040369 PMID:21266192 PMID:29193574 PMID:34272796
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
G
Casp8
caspase 8
increases expression increases activity multiple interactions
ISO
norcantharidin results in increased expression of CASP8 protein modified form norcantharidin results in increased activity of CASP8 protein Paclitaxel promotes the reaction [norcantharidin results in increased expression of CASP8 protein modified form]; U 0126 inhibits the reaction [norcantharidin results in increased expression of CASP8 protein modified form]
CTD
PMID:20040369 PMID:21266192 PMID:29193574 PMID:34272796
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
G
Casp9
caspase 9
multiple interactions increases activity increases expression
ISO
Paclitaxel promotes the reaction [norcantharidin results in increased expression of CASP9 protein modified form] norcantharidin results in increased activity of CASP9 protein
CTD
PMID:20040369 PMID:21266192 PMID:29193574 PMID:34272796
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
G
Ccn2
cellular communication network factor 2
decreases expression
EXP
norcantharidin results in decreased expression of CCN2 mRNA; norcantharidin results in decreased expression of CCN2 protein
CTD
PMID:18176075
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
G
Ccnb1
cyclin B1
decreases expression multiple interactions
ISO
norcantharidin results in decreased expression of CCNB1 protein Paclitaxel promotes the reaction [norcantharidin results in decreased expression of CCNB1 protein]
CTD
PMID:34272796
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Cdc25c
cell division cycle 25C
multiple interactions decreases expression
ISO
Paclitaxel promotes the reaction [norcantharidin results in decreased expression of CDC25C protein]
CTD
PMID:21266192 PMID:34272796
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
G
Cdh2
cadherin 2
decreases expression
ISO
norcantharidin results in decreased expression of CDH2 protein
CTD
PMID:15711181
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
increases phosphorylation
ISO
norcantharidin results in increased phosphorylation of CDKN1A protein
CTD
PMID:21266192
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Chek1
checkpoint kinase 1
increases phosphorylation
ISO
norcantharidin results in increased phosphorylation of CHEK1 protein
CTD
PMID:21266192
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
G
Chek2
checkpoint kinase 2
increases phosphorylation
ISO
norcantharidin results in increased phosphorylation of CHEK2 protein
CTD
PMID:21266192
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
G
Ddit3
DNA-damage inducible transcript 3
increases expression multiple interactions
ISO
norcantharidin results in increased expression of DDIT3 protein [norcantharidin co-treated with Paclitaxel] results in increased expression of DDIT3 protein; Paclitaxel promotes the reaction [norcantharidin results in increased expression of DDIT3 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of DDIT3 protein]
CTD
PMID:34272796
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
G
Dsg1
desmoglein 1
decreases expression
ISO
norcantharidin results in decreased expression of DSG1 protein
CTD
PMID:15711181
NCBI chr18:11,674,687...11,705,383
Ensembl chr18:11,674,402...11,703,443
G
Eif2s1
eukaryotic translation initiation factor 2 subunit alpha
increases phosphorylation multiple interactions
ISO
norcantharidin results in increased phosphorylation of EIF2S1 protein [norcantharidin co-treated with Paclitaxel] results in increased phosphorylation of EIF2S1 protein; Paclitaxel promotes the reaction [norcantharidin results in increased phosphorylation of EIF2S1 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased phosphorylation of EIF2S1 protein]
CTD
PMID:34272796
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
G
Ern1
endoplasmic reticulum to nucleus signaling 1
multiple interactions increases expression
ISO
Paclitaxel promotes the reaction [norcantharidin results in increased expression of ERN1 protein]
CTD
PMID:34272796
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
G
Fas
Fas cell surface death receptor
increases expression
ISO
norcantharidin results in increased expression of FAS protein
CTD
PMID:21266192
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
G
H2ax
H2A.X variant histone
increases expression multiple interactions
ISO
norcantharidin results in increased expression of H2AX protein modified form Paclitaxel promotes the reaction [norcantharidin results in increased expression of H2AX protein modified form]
CTD
PMID:34272796
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
G
Il2
interleukin 2
multiple interactions
ISO
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]; norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]]
CTD
PMID:21075198
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
G
Mapk1
mitogen activated protein kinase 1
increases phosphorylation
ISO
norcantharidin results in increased phosphorylation of MAPK1 protein
CTD
PMID:21075198 PMID:21266192
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
increases phosphorylation
ISO
norcantharidin results in increased phosphorylation of MAPK3 protein
CTD
PMID:21075198 PMID:21266192
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
G
Mapk8
mitogen-activated protein kinase 8
increases phosphorylation
ISO
norcantharidin results in increased phosphorylation of MAPK8 protein
CTD
PMID:21266192 PMID:29193574
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
G
Mapk9
mitogen-activated protein kinase 9
increases phosphorylation
ISO
norcantharidin results in increased phosphorylation of MAPK9 protein
CTD
PMID:29193574
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
G
Mcl1
MCL1 apoptosis regulator, BCL2 family member
decreases expression
ISO
norcantharidin results in decreased expression of MCL1 protein
CTD
PMID:21266192
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
G
Mmp2
matrix metallopeptidase 2
decreases activity
ISO
norcantharidin results in decreased activity of MMP2 protein
CTD
PMID:15711181
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
G
Mmp9
matrix metallopeptidase 9
multiple interactions decreases activity decreases expression
ISO
norcantharidin results in decreased expression of and results in decreased activity of MMP9 protein; SP1 protein affects the reaction [norcantharidin results in decreased expression of MMP9 mRNA] norcantharidin results in decreased activity of MMP9 protein
CTD
PMID:15711181 PMID:19616522
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Parp1
poly (ADP-ribose) polymerase 1
increases expression multiple interactions
ISO
norcantharidin results in increased expression of PARP1 protein modified form [norcantharidin co-treated with Paclitaxel] results in increased cleavage of PARP1 protein; Paclitaxel promotes the reaction [norcantharidin results in increased expression of PARP1 protein modified form]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased cleavage of PARP1 protein]
CTD
PMID:34272796
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
G
Pcna
proliferating cell nuclear antigen
decreases expression
ISO
norcantharidin results in decreased expression of PCNA protein
CTD
PMID:16681930
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
G
Rela
RELA proto-oncogene, NF-kB subunit
decreases expression
EXP
norcantharidin results in decreased expression of RELA mRNA; norcantharidin results in decreased expression of RELA protein
CTD
PMID:18176075
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Sirt2
sirtuin 2
decreases expression
ISO
norcantharidin results in decreased expression of SIRT2 mRNA
CTD
PMID:34272796
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
G
Sirt6
sirtuin 6
decreases expression
ISO
norcantharidin results in decreased expression of SIRT6 mRNA
CTD
PMID:34272796
NCBI chr 7:8,082,312...8,087,776
Ensembl chr 7:8,082,364...8,098,914
G
Sirt7
sirtuin 7
multiple interactions decreases expression
ISO
[norcantharidin co-treated with Paclitaxel] results in decreased expression of and affects the localization of SIRT7 protein; [norcantharidin co-treated with Paclitaxel] results in decreased expression of SIRT7 mRNA; Paclitaxel promotes the reaction [norcantharidin results in decreased expression of SIRT7 mRNA]; Paclitaxel promotes the reaction [norcantharidin results in decreased expression of SIRT7 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased cleavage of PARP1 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of ATF4 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased expression of DDIT3 protein]; SIRT7 protein inhibits the reaction [[norcantharidin co-treated with Paclitaxel] results in increased phosphorylation of EIF2S1 protein] norcantharidin results in decreased expression of SIRT7 mRNA; norcantharidin results in decreased expression of SIRT7 protein
CTD
PMID:34272796
NCBI chr10:105,896,476...105,903,301
Ensembl chr10:105,896,476...105,903,172
G
Sp1
Sp1 transcription factor
multiple interactions decreases activity
ISO
SP1 protein affects the reaction [norcantharidin results in decreased expression of MMP9 mRNA] norcantharidin results in decreased activity of SP1 protein
CTD
PMID:19616522
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
G
Stat1
signal transducer and activator of transcription 1
increases expression
ISO
norcantharidin results in increased expression of STAT1 protein
CTD
PMID:19616522
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
G
Stat3
signal transducer and activator of transcription 3
decreases phosphorylation
ISO
norcantharidin results in decreased phosphorylation of STAT3 protein
CTD
PMID:21266192
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
G
Stat5a
signal transducer and activator of transcription 5A
decreases phosphorylation
ISO
norcantharidin results in decreased phosphorylation of STAT5A protein
CTD
PMID:21266192
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
G
Stat5b
signal transducer and activator of transcription 5B
decreases phosphorylation
ISO
norcantharidin results in decreased phosphorylation of STAT5B protein
CTD
PMID:21266192
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
G
Thbs1
thrombospondin 1
increases expression
ISO
norcantharidin results in increased expression of THBS1 protein
CTD
PMID:16681930
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
G
Timp2
TIMP metallopeptidase inhibitor 2
increases expression
ISO
norcantharidin results in increased expression of TIMP2 mRNA; norcantharidin results in increased expression of TIMP2 protein
CTD
PMID:16681930
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
G
Vegfa
vascular endothelial growth factor A
decreases expression
ISO
norcantharidin results in decreased expression of VEGFA mRNA; norcantharidin results in decreased expression of VEGFA protein
CTD
PMID:16681930
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all
Path 1
CHEBI ontology
19899
chemical entity
19897
atom
19897
nonmetal atom
19820
oxygen atom
19560
oxygen molecular entity
19560
organooxygen compound
19215
oxacycle
17926
furofuran
72
(+)-(7R,7'R,7''R,7'''R,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol
0
(+)-(7R,7'R,7''R,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol
0
(+)-(7R,7'R,7''S,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol
0
(+)-sesamin +
17
(+)-sesamin dicatechol
0
(+)-sesamin monocatechol +
0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,8S,8'S)-4'-hydroxy-3,3',4,5,5'-pentamethoxy-7,9':7',9-diepoxylignane
0
(-)-demethoxylpinoresinol
0
(-)-medioresinol
0
(1S,3R,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-prop-1-en-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione
0
(1S,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-propan-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione
0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-\{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzyl\}propyl]carbamate
0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl glycolate
0
11,12-epoxy-5,6-seco-1,6(13)-tremuladien-5,12-olide
0
13-Hydroxymarasmene
0
14,15-dihydroajugapitin
0
14,15-dihydroclerodin
0
14-hydro-15-hydroxyajugachin A
0
14-hydro-15-hydroxyajugapitin
0
15-Hydroxymarasmen-3-one
0
15-epi-lupulin B
0
15-hydroxyajubractin C
0
1alpha,15-Dihydroxymarasmene
0
22-epi-methylatranone B
0
3-epi-14,15-dihydrocaryoptin
0
3-epi-caryoptin
0
3alpha,15-Dihydroxymarasmene
0
3beta-Dihydroxymarasmene
0
4-[(1S,3aR,4S,6aR)-4-(1,3-benzodioxol-5-yl)tetrahydrofuro[3,4-c]furan-1-yl]-2-methoxyphenol
0
4-epi-Ethiosolide
0
4alpha-hydroxypinoresinol
0
4beta-[(beta-D-glucopyranosyl)hydroxy]-pinoresinol
0
6-(7-methyloctyl)-1H,3H,4H,6H-furo[3,4-c]furan-1-one
0
6-hexyl-3-methyl-(3S,3aS,6R,6aR)-perhydrofuro[3,4-b]furan-2,4-dione
0
Agrocybolactone
0
Anhydromarasmone
0
Ascospiroketal A
0
Ascospiroketal B
0
Asperochrin E
0
Aspersclerotiorone C
0
Asteltoxin
0
Asteltoxin B
0
Asteltoxin C
0
Asteltoxin D
0
Asteltoxin E
0
Asteltoxin F
0
Atranone A
0
Atranone B
0
Atranone C
0
Atranone H
0
Atranone I
0
Atranone T
0
Atranone U
0
Avenaciolid 1
0
Avenaciolid 4
0
Avertoxin A
0
Avertoxin B
0
Avertoxin C
0
Avertoxin D
0
Cephalosporolide E
0
Cephalosporolide F
0
Cephalosporolide H
0
Cephalosporolide I
0
Clerodendrin A
0
Communiol D
0
Conosilane A
0
Dermatolactone
0
Diasteltoxin A
0
Diasteltoxin B
0
Diasteltoxin C
0
Dibetaeminin A
0
Dihydromarasmone
0
Discosiolide
0
Eremantholide A
0
Erythroskyrin
0
GS-8373
0
Gilluone A
0
Gymnodrimane D
0
Isoasteltoxin
0
Isomarasmone
0
Jodrellin A
0
LSM-4433
0
Mabetaarilactone A
0
Mabetaarilactone F
0
Mabetaarilactone acetonide
0
Manginoid E
0
Manginoid F
0
Marasmene
0
Marasmene B
0
Marasmone
0
NORCANTHARIDIN
48
Neglectine A
0
Nesteretal A
0
No. 2106 A
0
Penisporolide B
0
Protulactone A
0
Pseudonocardide D
0
Purpurogenolide A
0
Pyrenolide D
0
Rubetaulanorol-beta
0
Sculponeatin C
0
Spiroleptosphol T1
0
Spiroleptosphol T2
0
Spiroleptosphol W
0
Spiromabetaaritone
0
Syringolide 1
0
Syringolide 2
0
Taichunin A
0
Trichodermaketone A
0
Trichodermaketone B
0
Trichodermaketone E
0
V214w
0
Varioxiranol L
0
Velleratretraol
0
Virgineol
0
Xylobovide
0
[(1S,3R,7Z,9R,12S,13R,15R)-13-Butan-2-yl-13-hydroxy-3,12-dimethyl-4,11-dioxo-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-dien-7-yl]methyl acetate
0
ajubractin A
0
ajubractin B
0
ajubractin C
0
ajubractin D
0
ajubractin E
0
ajugapitin
0
alpha-mannofuranuronic acid gamma-lactone
0
aplysiallene
0
areptin A
0
areptin B
0
buddlenol C
0
caryoptin
0
clerodin
0
darunavir +
0
demethoxyaschantin
0
dihydrocanadensolide
0
ficusequilignan A
0
ivain II
0
lupulin A
0
pinoresinol +
7
salicifoliol
0
sesaminol +
0
sesaminol 2-O-beta-D-gentiobioside
0
sesaminol 2-O-beta-D-glucoside
0
sporothriolide
0
stemocurtisine
0
stemocurtisine N-oxide
0
syringaresinol +
11
Path 2
CHEBI ontology
19899
subatomic particle
19897
composite particle
19897
hadron
19897
baryon
19897
nucleon
19897
atomic nucleus
19897
atom
19897
main group element atom
19836
p-block element atom
19836
carbon group element atom
19776
carbon atom
19772
organic molecular entity
19772
organic molecule
19725
organic cyclic compound
19517
organic heterocyclic compound
18894
organic heteropolycyclic compound
18322
organic heterobicyclic compound
17272
furofuran
72
(+)-(7R,7'R,7''R,7'''R,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol
0
(+)-(7R,7'R,7''R,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol
0
(+)-(7R,7'R,7''S,7'''S,8S,8'S,8''S,8'''S)-4'',4'''-dihydroxy-3,3',3'',3''',5,5'-hexamethoxy-7,9':7',9-diepoxy-4,8'':4',8'''-bisoxy-8,8'-dineolignan-7'',7''',9'',9'''-tetraol
0
(+)-sesamin +
17
(+)-sesamin dicatechol
0
(+)-sesamin monocatechol +
0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''R,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5',5''-hexamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5,5'-pentamethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,7''S,8S,8'S,8''S)-4',4''-dihydroxy-3,3',3'',5-tetramethoxy-7,9':7',9-diepoxy-4,8''-oxy-8,8'-sesquineolignan-7'',9''-diol
0
(-)-(7R,7'R,8S,8'S)-4'-hydroxy-3,3',4,5,5'-pentamethoxy-7,9':7',9-diepoxylignane
0
(-)-demethoxylpinoresinol
0
(-)-medioresinol
0
(1S,3R,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-prop-1-en-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione
0
(1S,7Z,9R,12S,13R,15R)-13-Hydroxy-3,7,12-trimethyl-13-propan-2-yl-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-diene-4,11-dione
0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-\{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzyl\}propyl]carbamate
0
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl glycolate
0
11,12-epoxy-5,6-seco-1,6(13)-tremuladien-5,12-olide
0
13-Hydroxymarasmene
0
14,15-dihydroajugapitin
0
14,15-dihydroclerodin
0
14-hydro-15-hydroxyajugachin A
0
14-hydro-15-hydroxyajugapitin
0
15-Hydroxymarasmen-3-one
0
15-epi-lupulin B
0
15-hydroxyajubractin C
0
1alpha,15-Dihydroxymarasmene
0
22-epi-methylatranone B
0
3-epi-14,15-dihydrocaryoptin
0
3-epi-caryoptin
0
3alpha,15-Dihydroxymarasmene
0
3beta-Dihydroxymarasmene
0
4-[(1S,3aR,4S,6aR)-4-(1,3-benzodioxol-5-yl)tetrahydrofuro[3,4-c]furan-1-yl]-2-methoxyphenol
0
4-epi-Ethiosolide
0
4alpha-hydroxypinoresinol
0
4beta-[(beta-D-glucopyranosyl)hydroxy]-pinoresinol
0
6-(7-methyloctyl)-1H,3H,4H,6H-furo[3,4-c]furan-1-one
0
6-hexyl-3-methyl-(3S,3aS,6R,6aR)-perhydrofuro[3,4-b]furan-2,4-dione
0
Agrocybolactone
0
Anhydromarasmone
0
Ascospiroketal A
0
Ascospiroketal B
0
Asperochrin E
0
Aspersclerotiorone C
0
Asteltoxin
0
Asteltoxin B
0
Asteltoxin C
0
Asteltoxin D
0
Asteltoxin E
0
Asteltoxin F
0
Atranone A
0
Atranone B
0
Atranone C
0
Atranone H
0
Atranone I
0
Atranone T
0
Atranone U
0
Avenaciolid 1
0
Avenaciolid 4
0
Avertoxin A
0
Avertoxin B
0
Avertoxin C
0
Avertoxin D
0
Cephalosporolide E
0
Cephalosporolide F
0
Cephalosporolide H
0
Cephalosporolide I
0
Clerodendrin A
0
Communiol D
0
Conosilane A
0
Dermatolactone
0
Diasteltoxin A
0
Diasteltoxin B
0
Diasteltoxin C
0
Dibetaeminin A
0
Dihydromarasmone
0
Discosiolide
0
Eremantholide A
0
Erythroskyrin
0
GS-8373
0
Gilluone A
0
Gymnodrimane D
0
Isoasteltoxin
0
Isomarasmone
0
Jodrellin A
0
LSM-4433
0
Mabetaarilactone A
0
Mabetaarilactone F
0
Mabetaarilactone acetonide
0
Manginoid E
0
Manginoid F
0
Marasmene
0
Marasmene B
0
Marasmone
0
NORCANTHARIDIN
48
Neglectine A
0
Nesteretal A
0
No. 2106 A
0
Penisporolide B
0
Protulactone A
0
Pseudonocardide D
0
Purpurogenolide A
0
Pyrenolide D
0
Rubetaulanorol-beta
0
Sculponeatin C
0
Spiroleptosphol T1
0
Spiroleptosphol T2
0
Spiroleptosphol W
0
Spiromabetaaritone
0
Syringolide 1
0
Syringolide 2
0
Taichunin A
0
Trichodermaketone A
0
Trichodermaketone B
0
Trichodermaketone E
0
V214w
0
Varioxiranol L
0
Velleratretraol
0
Virgineol
0
Xylobovide
0
[(1S,3R,7Z,9R,12S,13R,15R)-13-Butan-2-yl-13-hydroxy-3,12-dimethyl-4,11-dioxo-10,14,16-trioxatetracyclo[7.5.1.13,6.012,15]hexadeca-5,7-dien-7-yl]methyl acetate
0
ajubractin A
0
ajubractin B
0
ajubractin C
0
ajubractin D
0
ajubractin E
0
ajugapitin
0
alpha-mannofuranuronic acid gamma-lactone
0
aplysiallene
0
areptin A
0
areptin B
0
buddlenol C
0
caryoptin
0
clerodin
0
darunavir +
0
demethoxyaschantin
0
dihydrocanadensolide
0
ficusequilignan A
0
ivain II
0
lupulin A
0
pinoresinol +
7
salicifoliol
0
sesaminol +
0
sesaminol 2-O-beta-D-gentiobioside
0
sesaminol 2-O-beta-D-glucoside
0
sporothriolide
0
stemocurtisine
0
stemocurtisine N-oxide
0
syringaresinol +
11